iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) announced management will attend investor conferences during JPM Week and BTIG Snowbird in winter 2026. Key events: LifeSci Advisors 15th Annual Corporate Access Event (one-on-one meetings, Jan 12, The Beacon Grand, San Francisco), additional JPM Week investor meetings (one-on-one, Jan 12–14, San Francisco), and BTIG 13th Annual Snowbird (one-on-one meetings and skiing, Feb 9–11, Cliff Lodge, Snowbird, Utah). The company provided contact instructions for scheduling in-person meetings via LifeSci Partners or BTIG sales representatives.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, IMDX gained 1.49%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
IMDX was down 1.07% while key diagnostics peers were mixed: BNR fell 20.53%, BDSX and MDXH were modestly negative, and FONR and PRE posted small gains. This pattern points to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Leadership appointment | Positive | -1.1% | Hired VP Medical Affairs to support transplant assay commercialization. |
| Jan 05 | Clinical/regulatory update | Positive | +4.3% | Reported GraftAssureDx de novo work ~95% complete and broad site engagement. |
| Nov 10 | Earnings and pipeline | Positive | +9.0% | Q3 2025 results with GraftAssureDx submission plans and registry build-out. |
| Nov 03 | Earnings pre-announcement | Positive | +1.8% | Set date for Q3 2025 results and highlighted upcoming investor conference. |
| Oct 13 | Leadership appointment | Positive | +4.6% | Named VP Marketing to drive 2026 commercial launch for GraftAssure family. |
Recent company updates, especially clinical and earnings-related milestones, have more often coincided with positive price reactions, while some organizational news has seen mild divergence.
Over the past few months, IMDX has steadily advanced its transplant diagnostics franchise. An October 13, 2025 leadership hire to support GraftAssure commercialization saw a 4.62% gain. Pre‑Q3 earnings communication on Nov 3, 2025 was followed by a 1.83% rise, and Q3 results on Nov 10, 2025 with $260,000 lab revenue and a planned 5,000‑participant registry led to an 8.97% move. A January 5, 2026 clinical update produced a 4.33% gain, while a January 6, 2026 medical‑affairs hire coincided with a modest 1.07% decline.
Market Pulse Summary
This announcement centers on IMDX’s investor-relations visibility, detailing participation in JPM Week and BTIG’s February conference, with one‑on‑one meetings scheduled from January 12–14, 2026 and February 9–11. In recent months, the company has highlighted progress toward GraftAssureDx submission and commercialization, alongside modest but growing revenue. Investors may watch for future updates that pair this outreach with concrete regulatory, commercial, or financial milestones to assess execution against the 2026 launch plans.
AI-generated analysis. Not financial advice.
NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference.
LifeSci Advisors 15th Annual Corporate Access Event
Date: Monday, January 12th
Location: The Beacon Grand, San Francisco, Calif.
Format: One-on-one meetings with management
Additional “JPM Week” Investor Meetings
Date: Monday, January 12th through Wednesday, January 14th
Location: San Francisco, Calif.
Format: One-on-one meetings with management
BTIG 13th Annual Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Date: February 9th – 11th
Location: Cliff Lodge, Snowbird, Utah
Format: One-on-one meetings and skiing with management
To request an in-person meeting with management on Monday, January 12th, during the week of the 44th Annual J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representatives Alexandra Grossman (alex@lifesciadvisors.com). For meetings at the BTIG conference, please contact your sales representative at BTIG.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.Insight Molecular Diagnostics.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
dfarrell@lifesciadvisors.com
FAQ
When will Insight Molecular Diagnostics (IMDX) meet investors during JPM Week 2026?
How can investors request an in-person meeting with IMDX management on Jan 12, 2026?
What are the dates and location for IMDX at the BTIG Snowbird conference?
What meeting formats will IMDX use at the LifeSci Advisors and BTIG events?
Who should IMDX investors contact for BTIG Snowbird meeting requests?
